{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:37:49Z","timestamp":1786995469292,"version":"build-2736575974"},"reference-count":90,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.path.2020.10.001","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T23:33:46Z","timestamp":1610235226000},"page":"151-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers"],"prefix":"10.1016","volume":"14","author":[{"given":"Doreen","family":"Palsgrove","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Allahabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.path.2020.10.001_bib1","unstructured":"Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents Volume VIII. IARC Scientific Publication No. 155."},{"key":"10.1016\/j.path.2020.10.001_bib2","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1158\/1055-9965.EPI-09-0638","article-title":"Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States","volume":"18","author":"Boukheris","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.path.2020.10.001_bib3","series-title":"WHO classification of head and neck tumours","author":"El-Naggar","year":"2017"},{"key":"10.1016\/j.path.2020.10.001_bib4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.annonc.2019.11.018","article-title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","volume":"31","author":"Kurzrock","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S1470-2045(10)70245-X","article-title":"Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review","volume":"12","author":"Laurie","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hed.20327","article-title":"Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group","volume":"28","author":"Gilbert","year":"2006","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib7","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1002\/hed.24682","article-title":"Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab","volume":"39","author":"Brown","year":"2017","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib8","doi-asserted-by":"crossref","first-page":"viii16","DOI":"10.1093\/annonc\/mdz384","article-title":"Identifying patients with NTRK fusion cancer","volume":"30","author":"Solomon","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib9","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/PAS.0000000000000980","article-title":"The role of molecular testing in the differential diagnosis of salivary gland carcinomas","volume":"42","author":"Skalova","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib10","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5858\/arpa.2016-0259-SA","article-title":"New developments in salivary gland pathology: clinically useful ancillary testing and new potentially targetable molecular alterations","volume":"141","author":"Griffith","year":"2017","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.path.2020.10.001_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/hed.25468","article-title":"Salivary gland tumors: molecular characterization and therapeutic advances for metastatic disease","volume":"41","author":"Schvartsman","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12105-020-01140-4","article-title":"Salivary gland cancer in the era of routine next-generation sequencing","volume":"14","author":"Todorovic","year":"2020","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jamaoto.2015.3930","article-title":"A\u00a020-year review of 75 cases of salivary duct carcinoma","volume":"142","author":"Gilbert","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.path.2020.10.001_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/PAS.0000000000000932","article-title":"MAML2 rearrangements in variant forms of mucoepidermoid carcinoma: ancillary diagnostic testing for the ciliated and warthin-like variants","volume":"42","author":"Bishop","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib15","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1078\/0344-0338-00136","article-title":"Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2\/neu oncoprotein overexpression","volume":"197","author":"Skalova","year":"2001","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.path.2020.10.001_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00428-019-02640-7","article-title":"Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland","volume":"476","author":"Bell","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.path.2020.10.001_bib17","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/PAS.0000000000001279","article-title":"Nuclear NR4A3 immunostaining is a specific and sensitive novel marker for acinic cell carcinoma of the salivary glands","volume":"43","author":"Haller","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y","article-title":"Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies","volume":"91","author":"Airoldi","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.path.2020.10.001_bib19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/oxfordjournals.annonc.a010770","article-title":"Phase II study on mitoxantrone in adenoid cystic carcinomas of the head and neck. EORTC Head and Neck Cancer Cooperative Group","volume":"7","author":"Verweij","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hed.2880140403","article-title":"Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck","volume":"14","author":"de Haan","year":"1992","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib21","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/oxfordjournals.annonc.a058665","article-title":"Epirubicin in patients with advanced or recurrent adenoid cystic carcinoma of the head and neck: a phase II study of the EORTC head and neck cancer cooperative group","volume":"4","author":"Vermorken","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/019459988609500206","article-title":"Chemotherapy for salivary gland cancer","volume":"95","author":"Kaplan","year":"1986","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.path.2020.10.001_bib23","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/1097-0142(19871215)60:12<2869::AID-CNCR2820601203>3.0.CO;2-Y","article-title":"Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin","volume":"60","author":"Dreyfuss","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.path.2020.10.001_bib24","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/1097-0142(19810215)47:4<645::AID-CNCR2820470404>3.0.CO;2-A","article-title":"Adriamycin\/cis-platinum\/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland","volume":"47","author":"Alberts","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.path.2020.10.001_bib25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1200\/JCO.1990.8.6.1056","article-title":"Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma","volume":"8","author":"Dimery","year":"1990","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3109\/00016489.2016.1170876","article-title":"Combination chemotherapy of carboplatin and paclitaxel for advanced\/metastatic salivary gland carcinoma patients: differences in responses by different pathological diagnoses","volume":"136","author":"Nakano","year":"2016","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.path.2020.10.001_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.oraloncology.2016.12.016","article-title":"Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm?","volume":"66","author":"Alfieri","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/2231-0770.102282","article-title":"Trastuzumab for Her2\/neu-positive metastatic salivary gland carcinoma: case report and review of the literature","volume":"2","author":"Firwana","year":"2012","journal-title":"Avicenna J Med"},{"key":"10.1016\/j.path.2020.10.001_bib29","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/hed.25392","article-title":"Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas","volume":"40","author":"Park","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1586\/era.10.226","article-title":"HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies","volume":"11","author":"Gajria","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.path.2020.10.001_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/hed.20614","article-title":"Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy","volume":"29","author":"Nabili","year":"2007","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib32","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S1368-8375(03)00097-6","article-title":"Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study","volume":"39","author":"Haddad","year":"2003","journal-title":"Oral Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib34","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/hed.20714","article-title":"Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy","volume":"30","author":"Prat","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib35","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1017\/S0022215108002314","article-title":"Biological therapy of salivary duct carcinoma","volume":"123","author":"Nashed","year":"2009","journal-title":"J\u00a0Laryngol Otol"},{"key":"10.1016\/j.path.2020.10.001_bib36","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1634\/theoncologist.2012-0369","article-title":"Trastuzumab for the treatment of salivary duct carcinoma","volume":"18","author":"Limaye","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.path.2020.10.001_bib37","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.oraloncology.2017.06.023","article-title":"Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine for metastatic salivary duct carcinoma","volume":"72","author":"van Boxtel","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib38","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.path.2020.10.001_bib39","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000488669","article-title":"Second-line treatment of HER2-positive salivary gland tumor: ado-trastuzumab emtansine (T-DM1) after progression on Trastuzumab","volume":"11","author":"Correa","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib40","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdz291","article-title":"Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric\/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q","volume":"30","author":"Jhaveri","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12105-013-0429-0","article-title":"Unmasking MASC: bringing to light the unique morphologic, immunohistochemical and genetic features of the newly recognized mammary analogue secretory carcinoma of salivary glands","volume":"7","author":"Bishop","year":"2013","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib45","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CCO.0000000000000527","article-title":"New approaches in salivary gland carcinoma","volume":"31","author":"Even","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib46","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK fusions: merits and limitations of current diagnostic platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.path.2020.10.001_bib47","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchio","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib48","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Skalova","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib50","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1535-7163.MCT-16-0909","article-title":"Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers","volume":"16","author":"Fuse","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.path.2020.10.001_bib52","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.path.2020.10.001_bib53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib54","doi-asserted-by":"crossref","unstructured":"Li J, Guo Y, Xue J, et\u00a0al First-in-human phase I study of anti-HER2 ADC MRG002 in patients with relapsed\/refractory solid tumors. DOI: 10.1200\/JCO.2020.38.15_suppl.TPS1101 Journal of Clinical Oncology 38, no. 15_suppl.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1101"},{"key":"10.1016\/j.path.2020.10.001_bib55","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/archotol.127.9.1075","article-title":"Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma","volume":"127","author":"Fan","year":"2001","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.path.2020.10.001_bib56","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A\u00a0prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib57","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1002\/hed.25857","article-title":"Prognostic markers in salivary gland cancer and their impact on survival","volume":"41","author":"Szewczyk","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10147-014-0674-6","article-title":"Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma","volume":"20","author":"Masubuchi","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1309\/RVTP1G0Q727WJUQD","article-title":"Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors","volume":"119","author":"Nasser","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib60","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/cancers9020017","article-title":"Androgen receptor signaling in salivary gland cancer","volume":"9","author":"Dalin","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.path.2020.10.001_bib61","first-page":"52","article-title":"Effective testosterone suppression for prostate cancer: is there a best castration therapy?","volume":"11","author":"Gomella","year":"2009","journal-title":"Rev Urol"},{"key":"10.1016\/j.path.2020.10.001_bib62","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"key":"10.1016\/j.path.2020.10.001_bib63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2018.12.035","article-title":"Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma","volume":"110","author":"van Boxtel","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.path.2020.10.001_bib65","first-page":"27","article-title":"Targeting RET-rearranged non-small-cell lung cancer: future prospects","volume":"10","author":"Bronte","year":"2019","journal-title":"Lung Cancer (Auckl)"},{"key":"10.1016\/j.path.2020.10.001_bib66","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0000000000000952","article-title":"Recurrent RET gene rearrangements in intraductal carcinomas of salivary gland","volume":"42","author":"Weinreb","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib68","doi-asserted-by":"crossref","unstructured":"Kutukova S, Imyanitov E, Raskin G, et\u00a0al Prognostic value of HER2, PD-L1 and RET mRNA expression in salivary gland tumor. DOI: 10.1200\/JCO.2020.38.15_suppl.e18534 Journal of Clinical Oncology 38, no. 15_suppl.","DOI":"10.1200\/JCO.2020.38.15_suppl.e18534"},{"key":"10.1016\/j.path.2020.10.001_bib70","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0002-9440(10)64408-2","article-title":"Large scale molecular analysis identifies genes with altered expression in salivary adenoid cystic carcinoma","volume":"161","author":"Frierson","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib71","doi-asserted-by":"crossref","first-page":"a002626","DOI":"10.1101\/mcs.a002626","article-title":"Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making","volume":"4","author":"Chahal","year":"2018","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1016\/j.path.2020.10.001_bib72","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.18632\/oncotarget.23641","article-title":"Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes","volume":"9","author":"Frerich","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.path.2020.10.001_bib73","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1158\/1940-6207.CAPR-15-0316","article-title":"Whole-genome sequencing of salivary gland adenoid cystic carcinoma","volume":"9","author":"Rettig","year":"2016","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.path.2020.10.001_bib74","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.bulcan.2019.05.003","article-title":"Systemic treatments of metastatic or locally recurrent adenoid cystic carcinoma of the head and neck, a systematic review","volume":"106","author":"Cherifi","year":"2019","journal-title":"Bull Cancer"},{"key":"10.1016\/j.path.2020.10.001_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13014-016-0617-7","article-title":"Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study","volume":"11","author":"Hsieh","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib76","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib77","first-page":"363","article-title":"Notch-4 contributes to the metastasis of salivary adenoid cystic carcinoma","volume":"24","author":"Ding","year":"2010","journal-title":"Oncol Rep"},{"key":"10.1016\/j.path.2020.10.001_bib78","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1172\/JCI128227","article-title":"Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma","volume":"129","author":"Ho","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.path.2020.10.001_bib79","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1200\/JCO.2020.38.15_suppl.3105","article-title":"A\u00a0phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed\/refractory non-Hodgkin lymphoma","volume":"38","author":"Zhang","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib80","doi-asserted-by":"crossref","unstructured":"Okuma HS, Yonemori K, Kojima Y, et\u00a0al Potentially targetable alterations identified in circulating tumor DNA (ctDNA) from patients (pts) with advanced rare cancers. DOI: 10.1200\/JCO.2020.38.15_suppl.e15540 Journal of Clinical Oncology 38, no. 15_suppl.","DOI":"10.1200\/JCO.2020.38.15_suppl.e15540"},{"key":"10.1016\/j.path.2020.10.001_bib81","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1200\/JCO.2020.38.15_suppl.6586","article-title":"Recurrent or metastatic salivary gland tumor (MSGT) patients treated with selinexor, a first in class selective exportin-1 (XPO1) inhibitor","volume":"38","author":"Malone","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.path.2020.10.001_bib82","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1097\/PAS.0000000000000912","article-title":"ETV6 gene rearrangements characterize a morphologically distinct subset of sinonasal low-grade non-intestinal-type adenocarcinoma: a novel translocation-associated carcinoma restricted to the sinonasal tract","volume":"41","author":"Andreasen","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib83","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PAS.0000000000000537","article-title":"Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion","volume":"40","author":"Skalova","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib84","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/PAS.0000000000000972","article-title":"Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases","volume":"42","author":"Skalova","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib85","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/his.13981","article-title":"Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion","volume":"76","author":"Xu","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.path.2020.10.001_bib86","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41467-018-08069-x","article-title":"Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands","volume":"10","author":"Haller","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.path.2020.10.001_bib87","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1097\/PAS.0000000000001258","article-title":"Diagnostic significance of HRAS mutations in epithelial-myoepithelial carcinomas exhibiting a broad histopathologic spectrum","volume":"43","author":"Urano","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib88","doi-asserted-by":"crossref","first-page":"18224","DOI":"10.18632\/oncotarget.4015","article-title":"Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity","volume":"6","author":"Grunewald","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.path.2020.10.001_bib89","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/path.2327","article-title":"POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands","volume":"215","author":"Moller","year":"2008","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib90","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/labinvest.3780249","article-title":"Molecular characterization of a new ALK translocation involving moesin (MSN-ALK) in anaplastic large cell lymphoma","volume":"81","author":"Tort","year":"2001","journal-title":"Lab Invest"},{"key":"10.1016\/j.path.2020.10.001_bib91","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41467-017-01178-z","article-title":"Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions","volume":"8","author":"Dalin","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.path.2020.10.001_bib92","doi-asserted-by":"crossref","first-page":"75893","DOI":"10.18632\/oncotarget.18173","article-title":"Somatic mutations in salivary duct carcinoma and potential therapeutic targets","volume":"8","author":"Khoo","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.path.2020.10.001_bib93","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/cncr.30179","article-title":"Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations","volume":"122","author":"Chiosea","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.path.2020.10.001_bib94","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/PAS.0000000000001301","article-title":"NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is \"intraductal\" correct?","volume":"43","author":"Skalova","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.path.2020.10.001_bib95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cancergen.2018.11.002","article-title":"Novel rearrangements involving the RET gene in papillary thyroid carcinoma","volume":"230","author":"Staubitz","year":"2019","journal-title":"Cancer Genet"},{"key":"10.1016\/j.path.2020.10.001_bib96","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/annonc\/mdy090","article-title":"RET fusions in a small subset of advanced colorectal cancers at risk of being neglected","volume":"29","author":"Pietrantonio","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187591812030074X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187591812030074X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:41:32Z","timestamp":1761748892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187591812030074X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S187591812030074X"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2020.10.001","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2020.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}